Drug

Dronabinol

In clinical development

ClassCannabinoid CB1 receptor agonistEmerging researchLate-stage developmentSteady momentum

Also known as (-)-delta9-trans-Tetrahydrocannabinol, .DELTA.1-THC, 1-trans-delta-9-Tetrahydrocannabinol, Delta-9-tetrahydrocannabinol+13 more

(-)-delta9-trans-Tetrahydrocannabinol, .DELTA.1-THC, 1-trans-delta-9-Tetrahydrocannabinol, Delta-9-tetrahydrocannabinol, Marinol, Syndros, THC, Tetrahydrocannabinol, delta 9-tetrahydrocannabinol, delta(1)-tetrahydrocannabinol, delta(9)-THC, delta-9-THC, delta9-tetrahydrocannabinol, tetrahydrocannabinol (THC), 3-Pentyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-dibenzo(b,d)pyran-1-ol, Dronabinolum, Synthetic delta-9-Tetrahydrocannabinol.

RxNorm10402 ChEMBLCHEMBL465 ATCA04AD10UNII7J8897W37S

Research papers

Active clinical trials

Cannabinoid receptor 1

Primary target

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

The Pharmacokinetics of a Hemp-Based Topical Cannabinoid Product in a Sanitized and Controlled Environment

Clinical trial2026-08-01Primary completion · ClinicalTrials.gov

Effects of Drugs on Stress Memories

Clinical trial2026-07-09Results posted · ClinicalTrials.gov

Cannabis Use, Cognition, and the Endocannabinoid System in HIV

Clinical trial2026-06-30Primary completion · ClinicalTrials.gov

Pharmacokinetics and Pharmacodynamics of Oral and Vaporized Delta-9-Tetrahydrocannabinol (THC) in Older Adults

Clinical trial2026-06-30Primary completion · ClinicalTrials.gov

The Effectiveness of Oral Cannabis Extracts for Osteoarthritic Pain: an Internal Pilot, Placebo Controlled, Blinded Randomized Trial

Clinical trial2026-06-22Results expected Q4 2026 · ClinicalTrials.gov

Challenging the Endocannabinoid System in Sleep Restricted Healthy Volunteers to Modulate Physiological Arousal (CANISLEEP) Study

Clinical trial2026-06-18Results expected Q4 2027 · ClinicalTrials.gov

Phase 1 Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans

Clinical trial2026-06-16Results expected Q4 2027 · ClinicalTrials.gov

The Effects of THC on Glucose Metabolism and Endothelial Function in Subjects With Type 2 Diabetes

Clinical trial2026-06-15Results expected Q4 2027 · ClinicalTrials.gov

Presynaptic nanoscale components of retrograde synaptic signaling.

Research2024-05-29Science advances

Cannabis effects on driving skills.

Research2012-12-07Clinical chemistry

Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea.

Research2012-01-30Neurogastroenterology and motility

Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome.

Research2011-07-29Gastroenterology

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Dronabinol

Aliases & brands

(-)-delta9-trans-Tetrahydrocannabinol.DELTA.1-THC1-trans-delta-9-TetrahydrocannabinolDelta-9-tetrahydrocannabinolMarinolSyndrosTHCTetrahydrocannabinoldelta 9-tetrahydrocannabinoldelta(1)-tetrahydrocannabinoldelta(9)-THCdelta-9-THCdelta9-tetrahydrocannabinoltetrahydrocannabinol (THC)3-Pentyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-dibenzo(b,d)pyran-1-olDronabinolumSynthetic delta-9-Tetrahydrocannabinol

RxNorm CUI

10402

ChEMBL ID

CHEMBL465

ATC codes

A04AD10

UNII

7J8897W37S

Primary mechanism

Cannabinoid CB1 receptor agonist